Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Mea

Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics (NASDAQ:ORKA), reported the direct sale of 9,854 shares of Common Stock for proceeds of approximately $687K across June 12 and June 15, 2026, according to the SEC Form 4 filing.

Post-transaction value (direct ownership)

Transaction value based on SEC Form 4 weighted average purchase price ($69.72); post-transaction value based on June 15, 2026 market close.

What was the structure and rationale behind these transactions?The activity combined exercise of 9,459 options (derivative securities) with immediate sale of 9,854 Common Stock shares.

How did this sale impact Agarwal's direct equity exposure?Direct Common Stock holdings declined from 26,753 to 16,899 shares, a 36.83% reduction.

Was indirect or entity-based ownership involved in this transaction?No; only direct ownership was affected, with no shares traded via trusts or other indirect entities, simplifying the transaction's attribution and impact assessment.

* 1-year performance calculated using June 15th, 2026 as the reference date.

Oruka Therapeutics develops monoclonal antibody therapies, including ORKA-001 and ORKA-002, targeting psoriasis and other i

Fuente original: Yahoo Finance (https://finance.yahoo.com/markets/stocks/articles/oruka-stock-now-nearly-700-194805181.html)